Adar Poonawala, CEO of SII, told ET that he has been speaking with partners who have the ability to develop a vaccine. However, he said there was no hurry as they assessed the situation.
He said SII will wait and see how the situation unfolds in the next 2-3 months. “We are talking with our partners and we are still evaluating whether this is needed because there are very few cases at the moment,” he said.
“Because it is not as contagious as Covid-19 and other diseases, so we have to decide whether to invest and efforts for it. We are already talking with our partners who have the ability to develop it, and we will wait and see in the next 2-3 months,” he told ET .
SII in Pune is the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses) which include polio, diphtheria, tetanus, pertussis, Hib, BCGhepatitis b, measles and mumpsAnd the rubella Beside pneumococcus and Covid-19 vaccines.
Danish biotechnology company North Bavarian (BAVA.CO) is the only company so far that has obtained permission from the European Commission for it Imphanix The vaccine to be marketed as protection against monkeypox, as recommended last week by European Medicines Agency (EMA).
India has so far reported four cases of monkeypox – three from Kerala and one from Delhi. The case identified in Delhi has no history of travel abroad. However, he went on a trip with his male friends to Himachal Pradesh on June 26 and fell ill on July 5. World Health Organization The global outbreak of monkeypox has been declared a “public health emergency of international concern,” one step after the pandemic. Observational studies say that smallpox vaccination is effective against monkeypox.